Chest
Original ResearchPulmonary HypertensionPulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry
Section snippets
Design Overview
The REVEAL Registry was designed by an independent Steering Committee, which oversaw study execution, data analysis, and reporting of the results. The design of the registry has been described in detail.26 The registry uses a multicenter prospective cohort design involving 54 centers in the United States (including 21 sites enrolling pediatric patients). The centers include diverse university-affiliated and community hospitals. Each of the four US Census Regions was represented.
Between March
Demographics
A total of 3,052 patients with clinically suspected WHO group I PAH were screened. Of these, 2,977 patients (97.2%) were enrolled. Ten patients were subsequently determined to have had inadvertent duplication of data; the duplicate entries were discarded, thereby yielding a final total of 2,967 patients. A total of 2,864 patients met the study entry criteria based on mean PAP, PCWP, and PVR at rest. Another 83 patients met the criteria at rest, substituting left ventricular end-diastolic
Discussion
The REVEAL Registry is the largest and most comprehensive registry of WHO group I PAH reported to date. The size of the study (2,967 patients), the number of referral sites and community practices, and geographical distribution make the results generalizable to clinical practice. No center enrolled more than 10% of the population. Importantly, by using a less-restrictive PCWP criterion of ≤ 18 mm Hg (as compared with the usual criterion of ≤ 15 mm Hg), the registry intentionally included
Acknowledgments
Author contributions: Dr Badesch: contributed to the study design; collection, analysis and interpretation of data; and drafting and critical review of the manuscript; and has seen and approved the final version.
Dr Raskob: contributed to the study design; collection, analysis and interpretation of data; drafting and critical review of the manuscript; and has seen and approved the final version.
Dr Elliott: contributed to the study design; collection, analysis and interpretation of data; drafting
References (41)
- et al.
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines
Chest
(2007) - et al.
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
Lancet
(2001) - et al.
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
J Am Coll Cardiol
(2006) - et al.
Ambrisentan therapy for pulmonary arterial hypertension
J Am Coll Cardiol
(2005) - et al.
Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension
Chest
(2000) - et al.
Temporal trends and drug exposures in pulmonary hypertension: an American experience
Am Heart J
(2006)
Design of the REVEAL registry for US patients with pulmonary arterial hypertension
Mayo Clin Proc
Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992
Obstet Gynecol
High prevalence of hypothyroidism in patients with primary pulmonary hypertension
Am J Med Sci
Hyperthyroidism and pulmonary hypertension
Respir Med
High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension
Chest
REVEAL registry: pediatric IPAH versus pediatric pulmonary vascular disease associated with congenital heart disease [abstract]
J Heart Lung Trans
REVEAL registry: comparison of patients with childhood-onset and adult-onset pulmonary vascular disease associated with congenital heart disease [abstract]
J Heart Lung Trans
REVEAL registry: comparison of patients with childhood-onset and adult-onset idiopathic pulmonary arterial hypertension [abstract]
J Heart Lung Trans
Evaluation and management of the patient with pulmonary arterial hypertension
Ann Intern Med
Primary pulmonary hypertension. A national prospective study
Ann Intern Med
Funding/Support: The REVEAL Registry is sponsored by Actelion Pharmaceuticals. Editorial support for the preparation of this manuscript was funded by Actelion Pharmaceuticals and provided by Jennifer M. Kulak, PhD, and Carol A. Lewis, PhD, from Wolters Kluwer.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml).